



UNICHEM
LABORATORIES LTD.

June 3, 2022

The Secretary
Listing Department
Bombay Stock Exchange Ltd.
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400 001

The Manager
Listing Department
National Stock Exchange of India Ltd
Exchange Plaza, Bandra – Kurla Complex
Bandra (East), Mumbai – 400 051

Scrip Code -506690

Stock Symbol – UNICHEMLAB

Sub: Disclosure of Related Party Transactions pursuant to Regulation 23(9) of the Securities and Exchange Board of India Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") for half year ended March 31, 2022

Dear Sir/Madam,

Pursuant to Regulation 23(9) of Listing Regulations, please find enclosed the disclosure of Related Party Transactions on a consolidated basis for half year ended March 31, 2022 drawn in accordance with the applicable Accounting Standards.

Kindly take the same on your records.

Thanking you,

Yours truly,
For UNICHEM LABORATORIES LIMITED



PRADEEP BHANDARI
Head Legal & Company Secretary

Encl : As above

UNICHEM LABORATORIES LIMITED
Disclosure of related party transactions for the half year ended 31st March, 2022
RELATED PARTY DISCLOSURES
Disclosure of related parties / related party transactions pursuant to Ind AS 24 "Related Party Disclosure"

Rs. in Lakhs

										Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.							
S. No	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty		Type of related party transaction	Value of the related party transaction as approved by the audit committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments				Details of the loans, inter-corporate deposits, advances or investments			
	Name	PAN	Name	PAN				Relationship of the counterparty with the listed entity or its subsidiary	Opening balance as on 1st October, 2021	Closing balance as on 31st March, 2022	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Cost	Tenure	Nature (loan/ advance/ inter-corporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured
1	Unichem Laboratories Ltd.		Niche Generics Limited.		Subsidiary (Wholly Owned)	Sale of finished goods / solvents (Net of returns)	1,041.23	1,041.23									
2	Unichem Laboratories Ltd.		Unichem SA Pty. LTD.		Subsidiary (Wholly Owned)	Sale of finished goods / solvents (Net of returns)	603.71	603.71									
3	Unichem Laboratories Ltd.		Unichem Farmaceutica Do Brasil Ltda		Subsidiary (Wholly Owned)	Sale of finished goods / solvents (Net of returns)	1,224.20	1,224.20									
4	Unichem Laboratories Ltd.		Unichem Pharmaceuticals (USA) Inc.		Subsidiary (Wholly Owned)	Sale of finished goods / solvents (Net of returns)	27,765.53	27,765.53									
5	Unichem Laboratories Ltd.		Unichem Laboratories Ltd (Ireland)		Subsidiary (Wholly Owned)	Sale of finished goods / solvents (Net of returns)	42.67	42.67									
6	Unichem Laboratories Ltd.		Unichem Pharmaceuticals (USA) Inc.		Subsidiary (Wholly Owned)	Reimbursements given (excluding indirect tax)	419.33	419.33									
7	Unichem Laboratories Ltd.		Unichem SA Pty. LTD.		Subsidiary (Wholly Owned)	Reimbursements given (excluding indirect tax)	100.24	100.24									
8	Unichem Laboratories Ltd.		Unichem Pharmaceuticals (USA) Inc.		Subsidiary (Wholly Owned)	Investments made	34.02	34.02									
9	Unichem Laboratories Ltd.		Niche Generics Limited		Subsidiary (Wholly Owned)	Guarantee commission income	14.19	14.19									
10	Unichem Laboratories Ltd.		Unichem Farmaceutica Do Brasil Ltda		Subsidiary (Wholly Owned)	Commission Expense	23.31	23.31									

S. No	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty		Type of related party transaction	Value of the related party transaction as approved by the audit committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments			Details of the loans, inter-corporate deposits, advances or investments				
	Name	PAN	Name	PAN				Relationship of the counterparty with the listed entity or its subsidiary	Opening balance as on 1st October, 2021	Closing balance as on 31st March, 2022	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Cost	Tenure	Nature (loan/ advance/ inter-corporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured
11	Unichem Laboratories Ltd.		Mrs Anita Mody		Relative of Key Management Personnel	Rent & Maintenance paid (excluding indirect taxes)	8.72	8.72									
12	Unichem Laboratories Ltd.		Uni - Distributors Pvt. Ltd.		Enterprise under significant influence of Key Management Personnel	Rent & Maintenance paid (excluding indirect taxes)	6.85	6.85									
13	Unichem Laboratories Ltd.		Uni Trust		Enterprise under significant influence of Key Management Personnel	Rent & Maintenance paid (excluding indirect taxes)	4.50	4.50									
14	Unichem Laboratories Ltd.		Dr. Prakash A. Mody		Key Management Personnel	Managerial remuneration (including defined contribution plan)	284.54	284.54									
15	Unichem Laboratories Ltd.		Mr. Dilip J Kunkolienkar		Key Management Personnel	Managerial remuneration (including defined contribution plan)	98.26	98.26									
16	Unichem Laboratories Ltd.		Ms Supriya Mody		Relative of Key Management Personnel	Salary (including defined contribution plan)	46.97	46.97									
17	Unichem Laboratories Ltd.		Unichem SA Pty. LTD.		Subsidiary (Wholly Owned)	Expenses Reimbursement	4.02	4.02									
18	Unichem Laboratories Ltd.		Unichem Pharmaceuticals (USA) Inc.		Subsidiary (Wholly Owned)	Expenses Reimbursement	89.31	89.31									
19	Unichem Laboratories Ltd.		Dr. (Mrs.) B. Kinnera Murthy		Independent Directors	Sitting Fees	7.00	7.00									
20	Unichem Laboratories Ltd.		Mr. Anand Y. Mahajan		Independent Directors	Sitting Fees	6.00	6.00									
21	Unichem Laboratories Ltd.		Mr. Prafull Anubhai		Independent Directors	Sitting Fees	7.50	7.50									
22	Unichem Laboratories Ltd.		Mr. Prafull D Sheth		Independent Directors	Sitting Fees	7.00	7.00									

S. No	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty		Type of related party transaction	Value of the related party transaction as approved by the audit committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments			Details of the loans, inter-corporate deposits, advances or investments				
	Name	PAN	Name	PAN				Relationship of the counterparty with the listed entity or its subsidiary	Opening balance as on 1st October, 2021	Closing balance as on 31st March, 2022	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Cost	Tenure	Nature (loan/ advance/ inter-corporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured
23	Unichem Laboratories Ltd.		Niche Generics Limited.		Subsidiary (Wholly Owned)	Trade Receivables		2,749.47	2,818.15								
24	Unichem Laboratories Ltd.		Unichem SA Pty. LTD.		Subsidiary (Wholly Owned)	Trade Receivables		405.57	583.54								
25	Unichem Laboratories Ltd.		Unichem Farmaceutica Do Brasil Ltda		Subsidiary (Wholly Owned)	Trade Receivables		3,832.23	3,963.10								
26	Unichem Laboratories Ltd.		Unichem Pharmaceuticals (USA) Inc.		Subsidiary (Wholly Owned)	Trade Receivables		18,023.56	19,865.42								
27	Unichem Laboratories Ltd.		Unichem Laboratories Ltd (Ireland)		Subsidiary (Wholly Owned)	Trade Receivables		31.48	92.07								
28	Unichem Laboratories Ltd.		Niche Generics Limited.		Subsidiary (Wholly Owned)	Trade Payables		21.79	2.28								
29	Unichem Laboratories Ltd.		Unichem SA Pty. LTD.		Subsidiary (Wholly Owned)	Trade Payables		1.21	1.62								
30	Unichem Laboratories Ltd.		Unichem Farmaceutica Do Brasil Ltda		Subsidiary (Wholly Owned)	Trade Payables		15.66	-								
31	Unichem Laboratories Ltd.		Unichem Pharmaceuticals (USA) Inc.		Subsidiary (Wholly Owned)	Trade Payables		15.03	10.59								
32	Unichem Laboratories Ltd.		Unichem Farmaceutica Do Brasil Ltda		Subsidiary (Wholly Owned)	Commission Payable		20.66	5.23								
33	Unichem Laboratories Ltd.		Niche Generics Limited *		Subsidiary (Wholly Owned)	Investments in subsidiaries in equity shares		7,029.03	6,909.36								
34	Unichem Laboratories Ltd.		Unichem SA Pty. LTD.		Subsidiary (Wholly Owned)	Investments in subsidiaries in equity shares		12.14	12.14								
35	Unichem Laboratories Ltd.		Unichem Farmaceutica Do Brasil Ltda		Subsidiary (Wholly Owned)	Investments in subsidiaries in equity shares		7,086.72	7,086.72								
36	Unichem Laboratories Ltd.		Unichem Pharmaceuticals (USA) Inc.*		Subsidiary (Wholly Owned)	Investments in subsidiaries in equity shares		3,582.39	3,200.25								

S. No	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty		Type of related party transaction	Value of the related party transaction as approved by the audit committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments			Details of the loans, inter-corporate deposits, advances or investments			
	Name	PAN	Name	PAN				Relationship of the counterparty with the listed entity or its subsidiary	Opening balance as on 1st October, 2021	Closing balance as on 31st March, 2022	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Cost	Tenure	Nature (loan/ advance/ inter-corporate deposit/ investment)	Interest Rate (%)	Tenure
37	Unichem Laboratories Ltd.		Unichem Laboratories Ltd (Ireland) *		Subsidiary (Wholly Owned)	Investments in subsidiaries in equity shares			2,145.27	2,104.84						
38	Unichem Laboratories Ltd.		Unichem (China) Pvt Ltd (China)		Subsidiary (Wholly Owned)	Investments in subsidiaries in equity shares			366.63	366.63						
39	Unichem Laboratories Ltd.		Niche Generics Limited.		Subsidiary (Wholly Owned)	Guarantees given (to the extent of facility availed by the subsidiaries)			2,591.10	2,539.82						
40	Unichem Laboratories Ltd.		Mrs Anita Mody		Relative of Key Management Personnel	Deposits paid			45.90	45.90						
41	Unichem Laboratories Ltd.		Uni - Distributors Pvt. Ltd.		Enterprise under significant influence of Key Management Personnel	Deposits paid			5.00	5.00						
42	Unichem Laboratories Ltd.		Uni Trust		Enterprise under significant influence of Key Management Personnel	Deposits paid			2.25	2.25						
43	Unichem Laboratories Ltd.		Dr. Prakash A. Mody		Key Management Personnel	Other Current Liabilities			61.93	66.23						
44	Unichem Laboratories Ltd.		Dr. (Mrs.) B. Kinnera Murthy		Independent Directors	Sitting Fees Payable			-	0.90						
45	Unichem Laboratories Ltd.		Mr. Anand Y. Mahajan		Independent Directors	Sitting Fees Payable			-	0.90						
46	Unichem Laboratories Ltd.		Mr. Prafull Anubhai		Independent Directors	Sitting Fees Payable			-	0.90						
47	Unichem Laboratories Ltd.		Mr. Prafull D Sheth		Independent Directors	Sitting Fees Payable			-	1.35						
48	Unichem Laboratories Ltd.		Unichem Laboratories Ltd - Employees Superannuation Fund		Post-employment benefit plans	Post-employment benefit plans:	50.65	50.65								
49	Unichem Laboratories Ltd.		Mr. Pradeep Bhandari		Key Management Personnel	Salary (including defined contribution plan)	52.29	52.29								

S. No	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty		Type of related party transaction	Value of the related party transaction as approved by the audit committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments			Details of the loans, inter-corporate deposits, advances or investments				
	Name	PAN	Name	PAN				Relationship of the counterparty with the listed entity or its subsidiary	Opening balance as on 1st October, 2021	Closing balance as on 31st March, 2022	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Cost	Tenure	Nature (loan/ advance/ inter-corporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured
50	Unichem Laboratories Ltd.		Mr. Sandip Ghume		Key Management Personnel	Salary (including defined contribution plan)	68.98	68.98									
51	Unichem Laboratories Ltd.		Synchron Research Services Pvt Ltd		Associate	Rent Income (net of indirect tax)	7.69	7.69									
52	Unichem Laboratories Ltd.		Synchron Research Services Pvt Ltd		Associate	Deposit refunded		7.50	-								
53	Unichem Laboratories Ltd.		Synchron Research Services Pvt Ltd		Associate	Capital Goods Purchased	461.14	461.14									
54	Unichem Pharmaceuticals (USA), Inc.		SJD Group, L.L.C.		Relative of Key Management Personnel of Subsidiary	Legal fees	44.58	44.58									
55	Unichem Pharmaceuticals (USA), Inc.		SJD Group, L.L.C.		Relative of Key Management Personnel of Subsidiary	Legal fees payable		-	3.52								
56	Niche Generics Limited		Unichem Laboratories Ltd. (Ireland)		Subsidiary of Parent Company	Loan given		111.55	108.95								
57	Unichem Laboratories Ltd. (Ireland)		Niche Generics Limited		Subsidiary of Parent Company	Loan taken		111.79	109.86								
58	Unichem SA (Pty) Ltd		I.F. Oliver		Directors and Other key management of Subsidiary	Salary (including defined contribution plan)	7.70	7.70									

* Decrease in investments represents guarantee commission receivable regrouped to trade receivables or realised during the year